| Stephen Edmund Friedrick, MD | |
|
401 15th Ave Se, Puyallup, WA 98372-3715 | |
| (253) 697-4000 | |
| Not Available |
| Full Name | Stephen Edmund Friedrick |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 28 Years |
| Location | 401 15th Ave Se, Puyallup, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205873205 | NPI | - | NPPES |
| FR2164 | Other | WA | BSWA |
| 0170834 | Other | WA | LIWA |
| FR2581 | Other | WA | BSWA |
| 0170822 | Other | WA | LIWA |
| 8244451 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD00037567 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Multicare Good Samaritan Hospital | Puyallup, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mt. Rainier Emergency Physicians, Pllc | 7810980968 | 39 |
| Western Washington Emergency Physicians Pllc | 0749514735 | 73 |
News Archive
The 2014 DIA patient fellows illustrate the power of patient advocacy. A Parkinson's disease patient is the driving force in the success of clinical trials, recruiting patients and transporting them to research sites while saving researchers thousands of dollars.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute today announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body's immune system to fight cancer at all levels-;from prevention to treatment and survivorship.
Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.
An experimental malaria drug was shown to effectively treat the disease in mice with only a single dose, according to a study published Thursday in the journal Science, Reuters reports (Kelland, 9/2). The new drug, known as NITD609, "represents an entirely new class of medicines to treat malaria ... Human trials, backed by Swiss pharmaceutical giant Novartis AG, could begin later this year," the Wall Street Journal writes (Naik, 9/3).
In future decades the need for effective strategies for medical rehabilitation will increase significantly, because patients' rate of survival after diseases with severe functional deficits, such as a stroke, will increase.
› Verified 5 days ago
| Entity Name | Mt. Rainier Emergency Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538104476 PECOS PAC ID: 7810980968 Enrollment ID: O20040406000189 |
News Archive
The 2014 DIA patient fellows illustrate the power of patient advocacy. A Parkinson's disease patient is the driving force in the success of clinical trials, recruiting patients and transporting them to research sites while saving researchers thousands of dollars.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute today announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body's immune system to fight cancer at all levels-;from prevention to treatment and survivorship.
Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.
An experimental malaria drug was shown to effectively treat the disease in mice with only a single dose, according to a study published Thursday in the journal Science, Reuters reports (Kelland, 9/2). The new drug, known as NITD609, "represents an entirely new class of medicines to treat malaria ... Human trials, backed by Swiss pharmaceutical giant Novartis AG, could begin later this year," the Wall Street Journal writes (Naik, 9/3).
In future decades the need for effective strategies for medical rehabilitation will increase significantly, because patients' rate of survival after diseases with severe functional deficits, such as a stroke, will increase.
› Verified 5 days ago
| Entity Name | Western Washington Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801352505 PECOS PAC ID: 0749514735 Enrollment ID: O20190625002379 |
News Archive
The 2014 DIA patient fellows illustrate the power of patient advocacy. A Parkinson's disease patient is the driving force in the success of clinical trials, recruiting patients and transporting them to research sites while saving researchers thousands of dollars.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute today announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body's immune system to fight cancer at all levels-;from prevention to treatment and survivorship.
Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.
An experimental malaria drug was shown to effectively treat the disease in mice with only a single dose, according to a study published Thursday in the journal Science, Reuters reports (Kelland, 9/2). The new drug, known as NITD609, "represents an entirely new class of medicines to treat malaria ... Human trials, backed by Swiss pharmaceutical giant Novartis AG, could begin later this year," the Wall Street Journal writes (Naik, 9/3).
In future decades the need for effective strategies for medical rehabilitation will increase significantly, because patients' rate of survival after diseases with severe functional deficits, such as a stroke, will increase.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Edmund Friedrick, MD 401 15th Ave Se, Puyallup, WA 98372-3715 Ph: () - | Stephen Edmund Friedrick, MD 401 15th Ave Se, Puyallup, WA 98372-3715 Ph: (253) 697-4000 |
News Archive
The 2014 DIA patient fellows illustrate the power of patient advocacy. A Parkinson's disease patient is the driving force in the success of clinical trials, recruiting patients and transporting them to research sites while saving researchers thousands of dollars.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute today announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body's immune system to fight cancer at all levels-;from prevention to treatment and survivorship.
Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.
An experimental malaria drug was shown to effectively treat the disease in mice with only a single dose, according to a study published Thursday in the journal Science, Reuters reports (Kelland, 9/2). The new drug, known as NITD609, "represents an entirely new class of medicines to treat malaria ... Human trials, backed by Swiss pharmaceutical giant Novartis AG, could begin later this year," the Wall Street Journal writes (Naik, 9/3).
In future decades the need for effective strategies for medical rehabilitation will increase significantly, because patients' rate of survival after diseases with severe functional deficits, such as a stroke, will increase.
› Verified 5 days ago
Paul M Billing, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1706 Meridian S, Suite 120, Puyallup, WA 98371 Phone: 253-848-8797 Fax: 253-446-3239 | |
Dr. Eric B Tulley, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 407 14th Ave Se, Puyallup, WA 98372 Phone: 253-848-6661 Fax: 253-770-5990 | |
Dr. Bobbi A Sipes, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 407 14th Ave Se, 407-14th Ave. Se, Pob 1247, Puyallup, WA 98372 Phone: 253-697-1848 | |
Dr. Michael John Regalado, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 407 14th Ave Se, Puyallup, WA 98372 Phone: 253-848-6661 Fax: 253-770-5990 | |
Dr. Ted Coleman, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 11102 Sunrise Blvd E, Suite 103, Puyallup, WA 98374 Phone: 253-848-8797 Fax: 253-845-0100 | |
Dr. Michael Perry Brook, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 407 14th Ave Se, Puyallup, WA 98372 Phone: 253-697-1848 Fax: 253-770-5990 |